Immunovant secures $450M private placement for IMVT-1402 development, while Biomea shifts focus to diabetes, and multiple companies announce deals and organizational changes.
L1 pioneer Lieping Chen has closed a new financing round. Normunity raised $75 million in a Series B, the company announced Monday, which it hopes to use to advance its lead program NRM-823 into the ...
Indian CDMO Aragen has secured a $100 million investment from Singapore-headquartered private equity firm Quadria Capital.
Eli Lilly, the most talked-about pharmaceutical company in recent years, is buying cancer startup Scorpion Therapeutics about ...
ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...
Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion in the biggest biotech M&A transaction ...
Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...
Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its ...
Regor Therapeutics' oral obesity drug RGT-075 shows 5% weight loss at 12 weeks in Phase 2a, trailing incretin pills from ...
Bayer's experimental Parkinson’s disease therapy made from stem cells will soon enter late-stage studies, marking a key test ...
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...
Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback